However, in my estimation, starting in 2026, this financial metric will resume growth, including due to Cobenfy, which was ...

In the last few decades, the biomedical research establishment has flipped from an academically-based enterprise to a ...

AbbVie (ABBV) took a big hit after an adult schizophrenia drug missed its primary endpoint in mid-stage trials. Analysts are ...

The GLORIOUS trial found that an intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) during heart surgeries ...